Roche seeks to freshen up Kadcyla label amid biosimilar defense

Roche aims to broaden use of its Kadcyla breast cancer drug as the Swiss pharmaceuticals giant defends itself against rivals who are moving in with copies of its older, patent-expired mainstay Herceptin.